ATE514708T1 - Transgene mausmodelle des hepatitis c virus (hcv) sowie identifizierung von hcv therapeutika - Google Patents

Transgene mausmodelle des hepatitis c virus (hcv) sowie identifizierung von hcv therapeutika

Info

Publication number
ATE514708T1
ATE514708T1 AT05810181T AT05810181T ATE514708T1 AT E514708 T1 ATE514708 T1 AT E514708T1 AT 05810181 T AT05810181 T AT 05810181T AT 05810181 T AT05810181 T AT 05810181T AT E514708 T1 ATE514708 T1 AT E514708T1
Authority
AT
Austria
Prior art keywords
hcv
compositions
hepatitis
virus
identification
Prior art date
Application number
AT05810181T
Other languages
English (en)
Inventor
Matti Sallberg
Lars Frelin
Original Assignee
Chrontech Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chrontech Pharma Ab filed Critical Chrontech Pharma Ab
Application granted granted Critical
Publication of ATE514708T1 publication Critical patent/ATE514708T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05810181T 2004-08-27 2005-08-26 Transgene mausmodelle des hepatitis c virus (hcv) sowie identifizierung von hcv therapeutika ATE514708T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60503004P 2004-08-27 2004-08-27
US64997505P 2005-02-04 2005-02-04
PCT/IB2005/003736 WO2006021896A2 (en) 2004-08-27 2005-08-26 Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics

Publications (1)

Publication Number Publication Date
ATE514708T1 true ATE514708T1 (de) 2011-07-15

Family

ID=35945114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810181T ATE514708T1 (de) 2004-08-27 2005-08-26 Transgene mausmodelle des hepatitis c virus (hcv) sowie identifizierung von hcv therapeutika

Country Status (4)

Country Link
US (1) US7566812B2 (de)
EP (1) EP1781690B1 (de)
AT (1) ATE514708T1 (de)
WO (1) WO2006021896A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080370B2 (en) 2006-09-28 2011-12-20 Osaka University Screening method for prophylactic and/or therapeutic agent for disease accompanied by hepatitis C
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009137111A1 (en) * 2008-05-09 2009-11-12 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
WO2010040756A1 (en) * 2008-10-06 2010-04-15 Virco Bvba Method for determining drug resistance mutations in any of the non-structural protein regions ns3 to ns5b of hepatitis c virus (hcv) for genotypes 1 to 6
CN101671694B (zh) * 2009-03-18 2013-04-17 中国人民解放军第四军医大学 一种调控表达丙型肝炎病毒ns3/ns4a蛋白酶的构建方法
WO2016086197A1 (en) 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
WO2016085876A1 (en) 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
EP3308786A1 (de) * 2016-10-13 2018-04-18 ETH Zurich Fgfr-regulierung zur behandlung von virusinfektionen
CN113948160B (zh) * 2020-07-15 2025-10-03 武汉Tcl集团工业研究院有限公司 一种药物筛选方法、设备及存储介质

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
AU719292B2 (en) 1996-07-24 2000-05-04 Chugai Seiyaku Kabushiki Kaisha Hepatitis C animal model
US6034297A (en) 1997-09-26 2000-03-07 Cedars-Sinai Medical Center In vivo, animal model for expression of hepatitis C virus
IT1299134B1 (it) * 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
US20040019920A1 (en) 1998-11-19 2004-01-29 Gala Design, Inc. Transgenic animals
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
US6509514B1 (en) 2000-03-17 2003-01-21 Kmt Hepatech, Inc. Chimeric animal model susceptible to human hepatitis C virus infection
JP2004000179A (ja) * 2002-03-29 2004-01-08 Toray Ind Inc Ｃ型慢性肝炎、肝硬変、肝癌病態を呈するモデル動物及びその作製方法

Also Published As

Publication number Publication date
WO2006021896A2 (en) 2006-03-02
US20080295185A1 (en) 2008-11-27
WO2006021896A3 (en) 2006-08-17
US7566812B2 (en) 2009-07-28
EP1781690A2 (de) 2007-05-09
EP1781690B1 (de) 2011-06-29

Similar Documents

Publication Publication Date Title
Rahbar Saadat et al. Host serine proteases: a potential targeted therapy for COVID-19 and influenza
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
Billoir et al. Phylogeny of the genus Flavivirus using complete coding sequences of arthropod-borne viruses and viruses with no known vector
Brecher et al. The flavivirus protease as a target for drug discovery
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
TW200716154A (en) Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
Oliveira et al. NS3 and NS5 proteins: important targets for anti-dengue drug design
ATE514708T1 (de) Transgene mausmodelle des hepatitis c virus (hcv) sowie identifizierung von hcv therapeutika
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
DE602005015452D1 (de) Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
ATE478889T1 (de) Neuartige verbindungen als hemmer von hepatitis c-virus ns3-serinprotease
DE602005015834D1 (de) 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
EA200700243A1 (ru) Способы лечения гепатита с
Blight et al. Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets.
NO20063205L (no) Inhibitorer for hepatitt C-virus NS3/NS4A-serinprotease
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
UY28525A1 (es) Péptidos macrociclicos activos contra en virus de la hepatitis c
Botting et al. Novel approaches to flavivirus drug discovery
WO2006109196A3 (en) Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
Marjomäki et al. Enteroviruses and coronaviruses: similarities and therapeutic targets
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
ATE337309T1 (de) Pyranon- und pyrandioninhibitoren der rna- abhängigen rna-polymerase des hepatitis-c-virus
Van Slyke et al. Vertebrate attenuated West Nile virus mutants have differing effects on vector competence in Culex tarsalis mosquitoes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties